Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

2.

Insufficient uptake of systematic search methods in oncological clinical practice guideline: a systematic review.

Trevisiol C, Cinquini M, Fabricio ASC, Gion M, Rutjes AWS.

BMC Med Res Methodol. 2019 Aug 20;19(1):180. doi: 10.1186/s12874-019-0818-5.

3.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

4.

Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice.

Ferraro S, Trevisiol C, Gion M, Panteghini M.

Clin Chem. 2018 Feb;64(2):270-278. doi: 10.1373/clinchem.2017.275263. Epub 2017 Oct 11. Review.

5.

Appropriateness of tumor marker request: a case of study.

Gion M, Trevisiol C, Fabricio ASC.

Ann Transl Med. 2017 Jul;5(13):274. doi: 10.21037/atm.2017.06.19.

6.

Epidemiology-based assessment of tumor marker overordering in breast cancer: an algorithm to examine different disease conditions.

Trevisiol C, Gion M, Dittadi R, Zappa M, Fabricio ASC.

Int J Biol Markers. 2017 Oct 31;32(4):e471-e473. doi: 10.5301/ijbm.5000274.

PMID:
28561878
7.

Indicators of inappropriate tumour marker use through the mining of electronic health records.

Gion M, Cardinali G, Trevisiol C, Zappa M, Rainato G, Fabricio ASC.

J Eval Clin Pract. 2017 Aug;23(4):895-902. doi: 10.1111/jep.12754. Epub 2017 May 15.

PMID:
28503788
8.

Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 3).

Gion M, Trevisiol C, Rutjes AWS, Rainato G, Fabricio ASC.

Int J Biol Markers. 2017 May 4;32(2):e147-e181. doi: 10.5301/ijbm.5000272. No abstract available.

PMID:
28475208
9.

Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 2).

Gion M, Trevisiol C, Rutjes AWS, Rainato G, Fabricio ASC.

Int J Biol Markers. 2017 Mar 2;32(1):e1-e52. doi: 10.5301/ijbm.5000259. No abstract available.

PMID:
28255982
10.

Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 1)

Gion M, Trevisiol C, Rutjes AW, Rainato G, Fabricio AS.

Int J Biol Markers. 2016 Dec 23;31(4):e332-e367. doi: 10.5301/jbm.5000251. No abstract available. Erratum in: Int J Biol Markers. 2017 Oct 31;32(4):e478.

PMID:
28025819
11.

An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study.

Gion M, Peloso L, Trevisiol C, Squarcina E, Zappa M, Fabricio AS.

Clin Chem Lab Med. 2016 Mar;54(3):473-82. doi: 10.1515/cclm-2015-0329.

PMID:
26351929
12.

An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests.

Gion M, Franceschini R, Rosin C, Trevisiol C, Peloso L, Zappa M, Fabricio AS; Working Group on Tumour Markers of Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC).

Clin Chem Lab Med. 2014 Jun;52(6):889-97. doi: 10.1515/cclm-2013-0708.

PMID:
24501159
13.

Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer.

Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A.

ISRN Obstet Gynecol. 2012;2012:245756. doi: 10.5402/2012/245756. Epub 2012 Jun 26.

14.

Beta defensin-1 gene (DEFB1) polymorphisms are not associated with atopic dermatitis in children and adolescents from northeast Brazil (Recife, Pernambuco).

Segat L, Guimarães RL, Brandão LA, Rocha CR, Zanin V, Trevisiol C, de Lima Filho JL, Crovella S.

Int J Dermatol. 2010 Jun;49(6):653-7. doi: 10.1111/j.1365-4632.2009.04343.x.

PMID:
20618470
15.

Secreted protein acidic and rich in cysteine (SPARC) gene polymorphism association with hepatocellular carcinoma in Italian patients.

Segat L, Milanese M, Pirulli D, Trevisiol C, Lupo F, Salizzoni M, Amoroso A, Crovella S.

J Gastroenterol Hepatol. 2009 Dec;24(12):1840-6. doi: 10.1111/j.1440-1746.2009.06009.x.

PMID:
19817957
16.

MBL expression in patients with recurrent tonsillitis.

Grasso DL, Segat L, Zocconi E, Radillo O, Trevisiol C, Crovella S.

Int J Pediatr Otorhinolaryngol. 2009 Nov;73(11):1550-3. doi: 10.1016/j.ijporl.2009.07.022. Epub 2009 Aug 27.

PMID:
19716183
17.

Tumour markers requesting pattern with regards to different organizational settings in Italy: a survey of hospital laboratories.

Franceschini R, Trevisiol C, Dittadi R, Gion M.

Ann Clin Biochem. 2009 Jul;46(Pt 4):316-21. doi: 10.1258/acb.2009.008240. Epub 2009 Jun 1.

PMID:
19487409
18.

MBL2 gene polymorphisms are correlated with high-risk human papillomavirus infection but not with human papillomavirus-related cervical cancer.

Segat L, Crovella S, Comar M, Milanese M, Zanotta N, Fabris A, Trevisiol C, Rossi T, De Seta F, Campello C.

Hum Immunol. 2009 Jun;70(6):436-9. doi: 10.1016/j.humimm.2009.03.006. Epub 2009 Mar 9.

PMID:
19275921
19.

Euglena gracilis ribonucleotide reductase: the eukaryote class II enzyme and the possible antiquity of eukaryote B12 dependence.

Torrents E, Trevisiol C, Rotte C, Hellman U, Martin W, Reichard P.

J Biol Chem. 2006 Mar 3;281(9):5604-11. Epub 2005 Dec 19.

20.

MBL2 polymorphisms screening in a regional Italian CF Center.

Trevisiol C, Boniotto M, Giglio L, Poli F, Morgutti M, Crovella S.

J Cyst Fibros. 2005 Sep;4(3):189-91.

Supplemental Content

Loading ...
Support Center